Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has reported the grant of stock options and restricted stock units (RSUs) to newly hired employees. The company granted:
- Non-qualified stock options to purchase 10,251 shares and 31,049 RSUs to 16 new non-executive employees
- Individually negotiated awards to Umberto La Magna, Senior VP, International, including options to purchase 40,286 shares and 28,213 RSUs
These awards, approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, have a grant and vesting commencement date of October 7, 2024. The stock options have an exercise price of $16.49 per share, a 10-year term, and vest over 4 years with 25% vesting annually. RSUs also vest 25% annually over 4 years.
Evolus, Inc. (NASDAQ: EOLS), un'azienda leader nella bellezza performante, ha annunciato la concessione di opzioni su azioni e unità di azioni vincolate (RSU) ai nuovi dipendenti assunti. L'azienda ha concesso:
- Opzioni su azioni non qualificate per l'acquisto di 10.251 azioni e 31.049 RSU a 16 nuovi dipendenti non esecutivi
- Premi negoziati individualmente per Umberto La Magna, VP Senior, Internazionale, compresi le opzioni per l'acquisto di 40.286 azioni e 28.213 RSU
Questi premi, approvati dal comitato per le compensazioni nell'ambito del Piano di Incentivo all'Induzione 2023 di Evolus, hanno una data di concessione e inizio maturazione fissata al 7 ottobre 2024. Le opzioni su azioni hanno un prezzo di esercizio di $16,49 per azione, una durata di 10 anni e maturano in 4 anni con il 25% che matura annualmente. Anche le RSU maturano il 25% annualmente su un periodo di 4 anni.
Evolus, Inc. (NASDAQ: EOLS), una empresa de belleza de rendimiento, ha reportado la concesión de opciones sobre acciones y unidades de acciones restringidas (RSUs) a los nuevos empleados contratados. La empresa otorgó:
- Opciones sobre acciones no calificadas para comprar 10,251 acciones y 31,049 RSUs a 16 nuevos empleados no ejecutivos
- Premios negociados individualmente para Umberto La Magna, VP Senior, Internacional, incluyendo opciones para adquirir 40,286 acciones y 28,213 RSUs
Estos premios, aprobados por el comité de compensación bajo el Plan de Incentivo por Inducción 2023 de Evolus, tienen una fecha de concesión y comienzo de adquisición de 7 de octubre de 2024. Las opciones sobre acciones tienen un precio de ejercicio de $16.49 por acción, un plazo de 10 años y se adquieren en 4 años con un 25% que se adquiere anualmente. Las RSUs también se adquieren al 25% anualmente durante 4 años.
Evolus, Inc. (NASDAQ: EOLS)는 성능 뷰티 회사로, 새로 채용된 직원들에게 주식 옵션 및 제한 주식 단위(RSU) 부여를 보고했습니다. 회사는 다음을 부여했습니다:
- 10,251주 매수 권리가 있는 비정규 주식 옵션과 16명의 비임원 신규 직원에게 31,049 RSU
- Umberto La Magna, 수석 부사장, 국제 부서에 대한 개별 협상 상여로 40,286주 매수 권리와 28,213 RSU
이 상여는 Evolus의 2023 유인 인센티브 계획에 따라 보상 위원회의 승인을 받았으며, 2024년 10월 7일에 부여 및 성과 시작일이 설정되었습니다. 주식 옵션의 행사가격은 $16.49 per 주이며, 기간은 10년이고, 4년 동안 25%씩 연도별로 성과 양도가 이루어집니다. RSU도 4년 동안 매년 25%씩 성과 양도됩니다.
Evolus, Inc. (NASDAQ: EOLS), une entreprise de beauté performante, a annoncé l'octroi de options d'achat d'actions et d'unités d'actions restreintes (RSU) à de nouveaux employés. L'entreprise a attribué :
- Des options d'achat d'actions non qualifiées pour acquérir 10.251 actions et 31.049 RSU à 16 nouveaux employés non exécutifs
- Des récompenses négociées individuellement pour Umberto La Magna, VP Senior, International, incluant des options pour acquérir 40.286 actions et 28.213 RSU
Ces récompenses, approuvées par le comité de rémunération dans le cadre du Plan d'Incitation à l'Induction 2023 d'Evolus, ont une date d'octroi et de début d'acquisition fixée au 7 octobre 2024. Les options d'achat d'actions ont un prix d'exercice de $16.49 par action, une durée de 10 ans et s'acquièrent sur 4 ans avec 25% s'acquérant annuellement. Les RSU s'acquièrent également à hauteur de 25% par an sur 4 ans.
Evolus, Inc. (NASDAQ: EOLS), ein Unternehmen für Leistungs-Beauty, hat die Gewährung von Aktienoptionen und beschränkten Aktieneinheiten (RSUs) an neu eingestellte Mitarbeiter bekannt gegeben. Das Unternehmen gewährte:
- Nicht qualifizierte Aktienoptionen zum Kauf von 10.251 Aktien und 31.049 RSUs an 16 neue nicht-executive Mitarbeiter
- Individuell verhandelte Prämien für Umberto La Magna, Senior VP, International, einschließlich Optionen zum Kauf von 40.286 Aktien und 28.213 RSUs
Diese Prämien, die vom Vergütungsausschuss im Rahmen des Evolus 2023 Inducement Incentive Plans genehmigt wurden, haben ein Datum für die Gewährung und den Beginn der Vesting am 7. Oktober 2024. Die Aktienoptionen haben einen Ausübungspreis von $16,49 pro Aktie, eine Laufzeit von 10 Jahren und vesten über 4 Jahre mit jährlich 25%. Auch die RSUs vesten über 4 Jahre zu je 25% jährlich.
- Granting of stock options and RSUs to attract and retain talent
- Individually negotiated awards for a senior executive position
- Four-year vesting schedule to encourage long-term employee retention
- None.
Additionally, the compensation committee approved the grant of individually negotiated awards to Umberto La Magna, Senior Vice President, International. Mr. La Magna’s awards include the grant of non-qualified stock options to purchase 40,286 shares of Evolus and 28,213 restricted stock units (RSUs) of the company’s common stock.
All these awards were approved by the compensation committee of the company’s board of directors under Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of October 7, 2024, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive
Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme® is a trademark of Symatese Aesthetics S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241011519557/en/
Evolus Contacts:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email: ir@evolus.com
Media:
Email: media@evolus.com
Source: Evolus
FAQ
What stock options and RSUs did Evolus (EOLS) grant to new employees?
What is the vesting schedule for the stock options and RSUs granted by Evolus (EOLS)?
What is the exercise price of the stock options granted by Evolus (EOLS) on October 7, 2024?
Under which plan were these inducement grants made by Evolus (EOLS)?
